

What is the effect of facility-level characteristics on continuation of contraceptive use?

A causal inference approach using
approximate balancing weights

Lucas Godoy Garraza¹, Carolina Cardona², Philip Anglewicz², and Leontine Alkema¹

¹ Department of Biostatistics & Epidemiology, University of Massachusetts Amherst

² Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-009639 and INV-008441].

In a nutshell...

- Does the facility where a woman receive FP services make any difference on contraceptive discontinuation?
 - Can we say, for example, that receiving FP in one facility is better than receiving FP somewhere else?
- We have data on facilities and their clients from Performance Monitoring for Action (PMA) in Kenya
- It is difficult to compare outcomes across facilities because facilities serve different populations.
- We use direct standardization to estimate the outcome we would have observed if all facilities served the same population (part 1)
- We check for “performance drivers” (part 2)


Data: Performance Monitoring for Action (PMA) Project Kenya 2020

- Sample of 399 facilities: facility characteristics (e.g., staff; LARC/SARC; stockouts; fees for FP services)
- Sample of 4,283 women 15-49 who visit one of these facilities for FP reasons: women's background characteristics (e.g., marital status, education, births, wealth)
- 90% follow up 4-6 month by phone: contraceptive “dynamics” (e.g., adoption, discontinuation, switching)

LARC: Long-Acting Reversible Contraception;
SARC: Short-Acting Reversible Contraception




The question: when looking at contraceptive discontinuation, does the FP facility makes any difference?



- A woman is considered to discontinue contraceptive use if at follow up she indicates that
 - she is no longer using the contraceptive received at baseline,
 - she has not switched to an alternative contraceptive,
 - she has no intention of becoming pregnant.
- Discontinuation rates across facilities ranges from 0 to about 20%

The issue: Why cannot we compare observed discontinuation across facilities?



Differences in outcomes may reflect differences in composition of population served (“client-mix”)

A counterfactual target: What would be the discontinuation had all facilities served the same population?

- For facility j , we observe the discontinuation among the women who attended that facility
- What we want is a **counterfactual**: what would be the discontinuation in facility j if it had served all women in our sample?

$$\mu_j = \frac{1}{n_j} \sum_{Z_i=j} m_j(X_i)$$

observed discontinuation

$$\mu_j^* = \frac{1}{n} \sum_{i=1}^n m_j(X_i)$$

counterfactual discontinuation

m_j : expected discontinuation in facility j for a woman with x characteristics

X_i : vector of characteristics of i^{th} woman

Z_i : facility indicator for the i^{th} woman

n_j : number of clients in facility j

n : total number of clients


Approach: How to estimate standardized discontinuation rates?

- We use an approach frequently used to address survey nonresponse
 - Our estimate is a weighted average of observed outcome in each facility
 - The weights (w) are chosen so that the distribution of covariate characteristics in each facility mimics the overall distribution
- Before weighting we clustered facilities to increase sample size
- After weighting we use regression to adjust remaining imbalances

$$\hat{\mu}_j^* = \sum_{Z_i=j} \hat{w}_i Y_i,$$


estimated counterfactual
discontinuation

Results: Did weighting decrease covariate imbalance across facilities?



→ After weighting, across-facility variation in woman characteristics reduces substantially


Results: Do standardized discontinuation rates vary across facilities?



- Standardized discontinuation vary across facilities but CIs overlap
- The Q-statistic is used in meta-analysis to detect “true” heterogeneity
 - If there is not true variation $Q \sim \chi^2_{J-1}$
- $Q = 113$, p-value $< .001$
- Estimated standard deviation across facilities $.027$ [95%CI: $.018$ -. $.038$]

2nd question: what facility-level characteristics are predictive of these differences?

- Meta-regression of estimated standardized outcome on facility-level characteristics
- We used nonparametric regression to capture nonlinear relationships and interactions
- Bayesian Additive Regression Tree (BART): combination of many simple trees to create a strong model



Example of tree identifying 3 groups with different expected discontinuity based on 2 facility-level characteristics

Preliminary results: identifying important characteristics


- Posterior inclusion probability (PIP): probability of using variable in the ensemble
- 4 predictors appeared to stand out with PIP > 80% (colored in blue)

Legend:


LARC: Long-Acting Reversible Contraception

SARC: Short-Acting Reversible Contraception

PERM: Permanent Contraception




Preliminary results: A low ratio of staff to visits predicted higher discontinuity




- Many facilities appeared to be “understaffed”
- An increase in the ratio of staff to new clients in the last month from 0 to .3 predicted a decrease in discontinuation of $-.033$ (80%CI: $-0.54, -.009$)

Preliminary results: FP fee predicted increased discontinuity




- Few facilities charge for FP services
- FP service fees predicted increase of discontinuity of .029 (80%CI: 0, .067)
 - Direction as expected
 - But modest and uncertain

Preliminary results: provision of certain services associated with higher discontinuity?



- Relationship of discontinuity with availability of delivery services is unclear
- Interactions with other variables?

Wrapping up



Lucas Godoy Garraza¹ (lgodoygarraz@umass.edu), Carolina Cardona², Philip Anglewicz², Leontine Alkema¹

¹ Department of Biostatistics & Epidemiology, University of Massachusetts Amherst

² Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health